NRx Pharmaceuticals, Inc. NRXP
3.00
(0.03)
(0.99%)
as of 25 Sep
- Market cap
- $131.2M
- P/E
- 0.0×
Follow NRXP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
170.77% | 146.18% | 125.92% | 131.22% | |
| (391.21%) | (344.70%) | (251.78%) | (120.41%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
133.19% | 145.86% | 139.78% | 618.36% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 22.15 | |
Free Cash Flow per Share |
(0.56) | (0.66) | (0.46) | (0.55) | |
Free Cash Flow |
(12.50) | (14.11) | (14.93) | (20.67) | |
Capital Expenditures |
— | — | — | (0.90) | |
Piotroski F-Score |
1.00 | 2.00 | 2.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
146.85% | 173.37% | 210.15% | (73.43%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 32.02 | |
Accounts Payable Turnover |
0.02 | 0.12 | 0.26 | 0.53 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
15,384.21 | 3,068.01 | 1,410.93 | 634.06 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 159.43% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 469.45% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 12.93% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.33 | 0.49 | 0.61 | 0.84 | |
Depreciation/Fixed assets |
0.68 | 2.30 | 1.19 | 0.52 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (1.86) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.09 | |
Operating CF per Share |
(0.56) | (0.66) | (0.46) | (0.53) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Capex to Sales |
— | — | — | 0.26 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (691.78%) |
Columns are period end dates